No abstract

Co-processed excipients may enhance functionality and reduce drawbacks of traditional excipients for the manufacture of tablets on a commercial scale. The following study aimed to characterize a range of co-processed excipients that may prove suitable for dispersible tablet formulations prepared by direct compression. The dosage form that is used the most is tablets. Their accessibility, simplicity of administration, consistency, and affordability are advantages. Direct compression is the most straightforward method for making tablets, despite the fact that it comes with several challenges, including those connected to the homogeneity and mass variation of the content, disintegration, dissolution, and the radial hardness of the tablets. In today's world, "co-processed excipients," which include frequently processed mixtures of fillers, binders, disintegrants, lubricants, and other excipients, are becoming more popular. Spray drying, fluid bed granulation, wet granulation, melt granulation, dry granulation, and co-crystallization are used to create these mixes. This review article lists technologies, co-processed excipients that are commercially available, and excipients that are typically utilized to make them.

Delivering a therapeutic agent to the desired site is the major problem in the treatment of many diseases such as cancer. Conventional utilization of drug is characterized by its limited biodistribution, its side effect, and lack of its selectivity. The poor solubility and large volume of distribution of anticancer drugs are the major problems in cancer therapy. Reducing size of drug and designing it into a suitable formulation and selecting a pathway for drug uptake is fundamental basis of nanotechnology. Great interest of nanoparticles is due their nanometer scale range. Their reduced particle size entails high surface area and hence a strategy for faster release. These particles are capable of deep penetration into the tissue without disrupting its functions. Thus, it has been suggested that nanoparticles should improve the therapeutic efficacy while decreasing the toxic side effects of anticancer drugs. The need for polymers with specific physical and biological properties has generated continued interest in novel polymer screening from natural resources.

Self-emulsifying drug delivery system (SEDDS), a type of lipid-based technology which are isotropic mixtures of oil, surfactant, solvent, and co-solvents generated by the activity of liquid or solid self-emulsifying ingredients onto powders. It shown interest in the recently for enhancement of solubility and bioavailability of poorly water-soluble drugs (BCS-II). With the novelty of research in this field, novel Excipients have been design with novel properties for enhances solubility, Bioavailabity and oral absorption to achieving target response. Self-emulsifying drug delivery systems (SEDDS) emerged as an insightful approach for delivering highly hydrophobic entities to enhance their bioavailability. SEDDS increase drug bioavailability in addition to improving the solubility of poorly soluble drugs by a number of additional potential pathways, such as avoiding the hepatic first-pass effect, blocking P-gp efflux, and overcoming resistance to metabolism by the cytochrome P450 family of enzymes in the gut and liver. Conventional SEDDS were developed in a liquid form which owned numerous overcome like low stability and drug loading efficiency, fewer choices of dosage forms and irreversible precipitation of drug or excipients. To address these curbs solid-SEDDS (S-SEDDS) was introduced as an efficient strategy that combined advantages of solid dosage forms such as increased stability, portability and patient compliance along with substantial improvement in the bioavailability. This review highlights parts of SEDDS, and their characterization evaluation. Which are completely summarized via different techniques.

The present work mainly emphasized on the enhancement of solubility of Ticagrelor by developing Self- Micro emulsifying drug delivery system. Ticagrelor is a BCS class IV drug with poor aqueous solubility and permeability. The saturated solubility of Ticagrelor in various oils, surfactants and co-surfactants was determined by using UV-spectroscopy. The excipients were selected based on their maximum solubility and compatibility for Ticagrelor. SMEDDS formulations od Ticagrelor were developed using different oils, surfactants and co-surfactant combinations (4:1 and 3:1). Pseudo ternary phase diagrams were constructed and based on pseudo ternary phase diagrams, Nano emulsification area was evaluated .Formulations were designed based on the pseudo ternary phase diagram using various proportions of oil (Capmul MCM E8 EP), surfactant (Labrasol), co-surfactant (PEG-400). The prepared formulations were selected among them F1 was optimized and carried out for further evaluations like dispersibility test, self-emulsification time ,phase separation and stability test, thermodynamic stability studies, droplet size and zeta potential, invitro drug release studies. The results of present study demonstrate that Ticagrelor SMEDDS can be used as a potential means for improving the solubility of Ticagrelor.